Sol-Gel Technologies Ltd. ( SLGL ) NASDAQ Global Market

Cena: 22.85 ( 0.79% )

Aktualizacja 08-25 21:58
NASDAQ Global Market
Branża: Biotechnology
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Sol-Gel Technologies Ltd., specjalna firma farmaceutyczna, koncentruje się na rozwijaniu i komercjalizacji miejscowych produktów leków dermatologicznych w oparciu o zastrzeżony system dostarczania mikrokapsułkowania w Izraelu. Główni kandydaci na produkty firmy to Twyneo, nowatorski, nietybiotyczny krem ​​do nietybiotycznego, który zakończył badania kliniczne fazy III w leczeniu trądziku vulgaris; Epsolay, krem ​​miejscowy raz na dobę, który zakończył badania kliniczne fazy III w leczeniu gruby rófloprzewodowej; SGT-210, który jest w badaniu klinicznym fazy I w leczeniu rogówki Palmoplantar; oraz erlotynib, tapinarof i roflumilast w leczeniu łuszczycy i innych schorzeń. Jest również zaangażowany w rozwój ogólnych miejscowych produktów leków dermatologicznych. Firma współpracuje z Perrigo. Sol-Gel Technologies Ltd. został włączony w 1997 r. I ma siedzibę w Ness Ziona w Izraelu.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 36
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 48.1556
Ilość akcji: Brak danych
Debiut giełdowy: 2018-02-01
WWW: https://www.sol-gel.com
CEO: Dr. Alon Seri-Levy
Adres: 7 Golda Meir Street
Siedziba: 7403650 Ness Ziona
ISIN: IL0011417206
Wskaźniki finansowe
Kapitalizacja (USD) 63 654 616
Aktywa: 42 980 000
Cena: 22.85
Wskaźnik Altman Z-Score: -6.0
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -18.7
Ilość akcji w obrocie: 48%
Średni wolumen: 22 353
Ilość akcji 2 785 760
Wskaźniki finansowe
Przychody TTM 11 707 000
Zobowiązania: 8 275 000
Przedział 52 tyg.: 4.01 - 26.89
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -1.2
P/E branży: 28.3
Beta: 1.603
Raport okresowy: 2025-11-14
WWW: https://www.sol-gel.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Alon Seri-Levy Co-Founder, Chief Executive Officer & Director 411 000 1961
Mr. Gilad Mamlok Advisor 367 000 1968
Dr. Itzik Yosef Chief Operating Officer 236 000 1976
Prof. David Avnir Co-Founder 0 0
Mr. Eyal Ben-Or Chief Financial Officer 0 0
Dr. Karine Neimann Vice President of Projects & Planning and Chief Chemist 0 1971
Mr. Moshe Arkin Executive Chairman of the Board 0 1953
Ms. Tamar Fishman Jutkowitz Vice President & General Counsel 0 1976
Wiadomości dla Sol-Gel Technologies Ltd.
Tytuł Treść Źródło Aktualizacja Link
Sol-Gel Announces Reverse Share Split NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse Split”) of the Company's issued and outstanding ordinary shares, par value NIS 0.1 per share (the “Ordinary Shares”), at the ratio of 10-for-1, such that each ten (10) Ordinary Shares shall be consolidated into one (1) Ordinary Share. globenewswire.com 2025-05-01 11:00:00 Czytaj oryginał (ang.)
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. Sol-Gel to receive $16 million during 2025 Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have already completed the trial NESS ZIONA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced it has entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma) for the sale and exclusive license of the U.S. rights to EPSOLAY and TWYNEO. globenewswire.com 2025-04-17 12:40:00 Czytaj oryginał (ang.)
Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis This detailed market intelligence publication offers valuable insights into the innovative technologies, competitive landscape, and emerging opportunities that are reshaping the global surface engineering industry through 2035. This detailed market intelligence publication offers valuable insights into the innovative technologies, competitive landscape, and emerging opportunities that are reshaping the global surface engineering industry through 2035. globenewswire.com 2025-04-07 14:01:00 Czytaj oryginał (ang.)
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know Sol-Gel's fourth-quarter 2024 earnings are likely to have gained from higher licensing revenues from its partners. zacks.com 2025-02-25 13:05:28 Czytaj oryginał (ang.)
Is SolGel Technologies (SLGL) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2024-12-25 12:41:13 Czytaj oryginał (ang.)
SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2024-11-20 15:00:35 Czytaj oryginał (ang.)
Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.13. zacks.com 2024-11-15 11:11:34 Czytaj oryginał (ang.)
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholders Phase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activated SGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update. globenewswire.com 2024-11-15 09:00:00 Czytaj oryginał (ang.)
SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now After losing some value lately, a hammer chart pattern has been formed for SolGel Technologies (SLGL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. zacks.com 2024-09-17 14:55:26 Czytaj oryginał (ang.)
All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com 2024-08-27 17:01:49 Czytaj oryginał (ang.)
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA) drug product generic to Zoryve® Cream (roflumilast cream 0.3%) Following management realignment, Mr. Mori Arkin, the Company's executive chairman and controlling shareholder to be appointed as Company's interim CEO as of January 1, 2025, subject to shareholders approval Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY in Europe and South Africa and is negotiating additional license deals in Latin America and other territories NESS ZIONA, Israel, Aug. 17, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. globenewswire.com 2024-08-17 15:27:00 Czytaj oryginał (ang.)
Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates Sol-Gel Technologies Ltd. (SLGL) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. zacks.com 2024-08-16 13:10:43 Czytaj oryginał (ang.)
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA)drug product generic to Zoryve® Cream(roflumilast cream 0.3%) Following management realignment, Mr. Mori Arkin, the Company's executive chairman and controlling shareholder to be appointed as Company's interim CEO as of January 1, 2025, subject to shareholders approval Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY in Europe and South Africa and is negotiating additional license deals in Latin America and other territories NESS ZIONA, Israel, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. globenewswire.com 2024-08-16 11:00:00 Czytaj oryginał (ang.)
Sol-Gel Technologies Announces Management Realignment NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that the Chief Executive Officer, Dr. Alon Seri-Levy, has recently advised the Sol-Gel Board of Directors of his desire to step down from his position as CEO and member of the Board. globenewswire.com 2024-07-15 11:00:00 Czytaj oryginał (ang.)
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China, Hong Kong, Macau, Taiwan and Israel, for a total consideration of up to $115 million. globenewswire.com 2024-05-20 11:00:00 Czytaj oryginał (ang.)
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it has signed an asset purchase agreement with Chinese based Shenzhen Beimei Pharmaceutical Co. Ltd, for the commercialization of TWYNEO, for the treatment of acne vulgaris, in the mainland of China, Hong Kong, Macau, Taiwan and Israel. globenewswire.com 2024-05-16 10:00:00 Czytaj oryginał (ang.)
Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream NESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that Padagis Israel Pharmaceuticals Ltd (“Padagis”), Sol-Gel's collaboration partner, submitted a first-to-file Abbreviated New Drug Application (“ANDA”) to the U.S. Food and Drug Administration (“FDA”) for Roflumilast Cream, 0.3%, a drug product generic to Zoryve® Cream (roflumilast cream, 0.3%), indicated for the treatment of plaque psoriasis in patients six years of age and older. globenewswire.com 2024-04-01 11:00:00 Czytaj oryginał (ang.)
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib gel, 2%), an Orphan Drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome and partnered with Galderma to commercialize two approved large-category dermatology products, TWYNEO® and EPSOLAY®, in the U.S, today announced financial results for the full year ended December 31st, 2023 and provided a corporate update. globenewswire.com 2024-03-13 09:00:00 Czytaj oryginał (ang.)
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it has begun Phase 3 testing of SGT-610 (patidegib gel, 2%) for Gorlin syndrome with the first patient screened. SGT-610 is a new topical hedgehog inhibitor being developed to prevent the new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors. Patidegib was acquired by Sol-Gel from PellePharm and is currently the only therapy in development to prevent the development of new BCC lesions in Gorlin syndrome patients. globenewswire.com 2023-11-30 09:00:00 Czytaj oryginał (ang.)
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610 NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced it will host a virtual KOL event on Wednesday, December 6, 2023 at 12:00 PM ET. To register, click here . globenewswire.com 2023-11-28 10:06:00 Czytaj oryginał (ang.)
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update NESS ZIONA, Israel, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. globenewswire.com 2023-11-09 09:00:00 Czytaj oryginał (ang.)
3 Generic Drug Stocks to Watch Amid Improving Market Prospects The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL. zacks.com 2023-10-30 13:17:43 Czytaj oryginał (ang.)
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, EPSOLAY and TWYNEO, today announced that the Company will virtually present at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023. globenewswire.com 2023-08-30 12:00:00 Czytaj oryginał (ang.)
Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26. zacks.com 2023-08-10 14:01:29 Czytaj oryginał (ang.)